Golden Matrix Reports First Quarter Financial Results With Record Revenues of $11.84 Million
LAS VEGAS, NV, March 14, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – Golden Matrix Group Inc. (NASDAQ:GMGI), developer, licensor and […]
Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit
FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (NASDAQ: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived […]
Stonepeak Completes Acquisition of Textainer
NEW YORK and HAMILTON, Bermuda, March 14, 2024 (GLOBE NEWSWIRE) — Stonepeak, a leading alternative investment firm specializing in infrastructure […]
SEALSQ Launches SEALBOX TM
Geneva, Switzerland, March 14, 2024 (GLOBE NEWSWIRE) — SEALSQ Corp (Nasdaq: LAES) (“SEALSQ” or “Company”), a leader in semiconductor, […]
Northann Corp Announces Plan of Strategic Relocation of Corporate Headquarters
ELK GROVE, Calif., March 14, 2024 (GLOBE NEWSWIRE) — Northann Corp (NYSE American: NCL) (“Northann” or the “Company”), a leading […]
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical […]
TSX News -
Coveo Wins CMSWire IMPACT Award for Best Use of AI in Customer Service with Coveo Relevance Generative Answering
MONTREAL and SAN FRANCISCO, March 14, 2024 (GLOBE NEWSWIRE) — Coveo (TSX:CVO), a leading provider of enterprise AI platforms that enable […]
LPL Financial Welcomes Five Independent Teams With $700 Million of AUM
SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that seven financial advisors from five firms […]
Sprout Social Names Crystal Boysen as Chief People Officer
CHICAGO, March 14, 2024 (GLOBE NEWSWIRE) — Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of […]
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for Efficacy Complete Response of Non-Target Tumor Also […]
